RARE DISEASE
Succinic semialdehyde dehydrogenase deficiency
Succinic semialdehyde dehydrogenase deficiency
Succinic semialdehyde dehydrogenase deficiency
Synonyms: 4-hydroxybutyric aciduria, Gamma-hydroxybutyric aciduria, SSADH deficiency
Synonyms: 4-hydroxybutyric aciduria, Gamma-hydroxybutyric aciduria, SSADH deficiency
Synonyms: 4-hydroxybutyric aciduria, Gamma-hydroxybutyric aciduria, SSADH deficiency
Drug discovery
2
drugs
With orphan designations
Overview
Succinic semialdehyde dehydrogenase deficiency (SSADHD) is a rare autosomal recessive neurometabolic disorder caused by ALDH5A1 gene mutations, leading to impaired degradation of GABA. This results in toxic accumulation of γ-hydroxybutyrate (GHB) and GABA, causing developmental delays, hypotonia, seizures, ataxia, and neuropsychiatric symptoms (e.g., hyperactivity, anxiety, OCD). Diagnosis is confirmed via elevated urinary GHB, genetic testing, and reduced SSADH enzyme activity. Treatment remains supportive, targeting symptom management with anticonvulsants, behavioral therapies, and multidisciplinary care, although experimental therapies like enzyme replacement are under investigation [1][6][11][16].
Burden
Chronic neurodevelopmental disability (e.g., intellectual impairment, speech delays) and progressive psychiatric symptoms (e.g., psychosis, aggression) in 50% of patients [6][8].
High care dependency due to seizures, ataxia, and sleep disturbances. Risk of sudden unexpected death in epilepsy (SUDEP) [6][19].
Therapies
Symptomatic management: Levetiracetam, lamotrigine (seizures); risperidone, methylphenidate (behavioral issues); physical/speech therapy [8][16].
Emerging therapies: Phase II trial of GABA-B receptor antagonist SGS-742; preclinical gene/enzyme replacement therapies showing promise in murine models [3][12][15].
Categories: rare genetic diseases, rare inborn errors of metabolism, rare neurological diseases
Research Papers
99 drug discovery papers about Succinic semialdehyde dehydrogenase deficiency, with 2 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
99 drug discovery papers about Succinic semialdehyde dehydrogenase deficiency, with 2 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-04-28 | Memantine Repurposing for NMDA-mediated Excitotoxicity
Memantine's uncompetitive NMDA receptor antagonism provides neuroprotection against excitotoxicity resulting from GABAergic dysfunction in SSADH deficiency. The drug's voltage-dependent blocking mechanism preserves physiological NMDA signaling while preventing pathological calcium influx during seizure activity and metabolic stress.
2026-04-03 | Postnatal gene restoration in succinic semialdehyde dehydrogenase deficiency (SSADHD) reveals phenotype reversibility.
Succinic semialdehyde dehydrogenase deficiency (SSADHD) is a rare autosomal recessive metabolic disorder due to loss-of-function ALDH5A1 mutations impairing the catabolism of γ-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the brain. In SSADHD, pathologic accumulation of GABA and its metabolic by-product γ-hydroxybutyrate (GHB) corresponds to a clinical syndrome dominated by developmental delay and epilepsy in half of patients with risk of sudden death in adolescence and adulthood. Brain-wide ALDH5A1 gene replacement for SSADHD is unavailable, and whether such treatment will reverse the SSADHD phenotype is unknown. We developed an inducible mouse SSADHD model, Aldh5a1 lox-STOP , enabling Cre-dependent Aldh5a1 restoration to evaluate gene therapy feasibility. In the absence of SSADH, Aldh5a1 lox-STOP mice exhibit hyperactivity and excessive serum GHB levels, culminating in death by ∼postnatal day 22, recapitulating the severe SSADHD condition. Systemic delivery of a blood-brain barrier (BBB)-penetrating adeno-associated virus (AAV) carrying a Cre gene to Aldh5a1 lox-STOP mice leads to brain-wide SSADH restoration, serum GHB level reduction, normalization of hyperactivity, and substantial increase in survival. As a step toward clinical translation, we further assessed an AAV encompassing a functional native promoter (FLnP) of ALDH5A1 tethered to its human coding sequence, namely AAV-FLnP-hALDH5A1. Aldh5a1 lox-STOP mice were effectively rescued when treated with AAV-FLnP-hALDH5A1 packaged in the blood-brain barrier (BBB)-penetrating capsid PHP.eB. These findings provide preclinical proof that SSADH gene replacement therapy is feasible and potentially effective.
2025-08-25 | Rational design and applications of piperazine and cyclohexane ionizable lipids for PKU and SSADH deficiency
A significant challenge of mRNA-based protein replacement therapies is the diminishing efficacy and escalating toxicity associated with repeated dosing of lipid nanoparticles (LNPs). Many existing lipid formulations were originally designed for vaccine and are not optimized for therapeutic applications. We developed two libraries of ionizable lipids—one based on piperazine and the other on a newly introduced cyclohexane structure—with variations in linker and tail groups to enhance molecular diversity. GC Biopharma’s cyclohexane- and piperazine-based LNPs (GCP LNPs) supported stable and high-level expression without inducing liver toxicity under repeated dosing regimens. These LNPs effectively corrected disease markers in mouse models of phenylketonuria (PKU) and succinic semialdehyde dehydrogenase (SSADH) deficiency. Specially, we observed that the rigid structure and chemical stability of cyclohexane-based lipids contributed to sustained delivery performance. These findings offer a promising direction for the development of LNPs suitable for chronic mRNA-based therapies.
2025-08-06 | Severe epilepsy phenotypes in adults with succinic semialdehyde dehydrogenase deficiency: Novel clinical and therapeutic insights from an Italian multicenter retrospective cohort study.
To describe the epileptic phenotypes in a series of adults with succinic semialdehyde dehydrogenase deficiency (SSADHD) and to evaluate the efficacy of novel treatments. We retrospectively reviewed the charts from seven adult patients followed at four Italian Epilepsy Centers. All cases had biallelic variants in the ALDH5A1 gene; three of these were novel: c.1205T>A (p.Val402Glu), c.1630delT (p.Cys544Valfs*15), and c.141C>G (p.Tyr47Ter). Patients (age at last follow-up: 33.8 ± 8.8 years) had moderate motor deficits and variable degrees of intellectual disability, often with psychiatric symptoms. Epilepsy had heterogeneous presentations, with a mean onset age of 13.1 ± 7.7 years. Drug-resistant seizures and convulsive status epilepticus (SE) occurred in five and three patients respectively; two had possible sudden unexpected death in epilepsy. Prolonged episodes of impaired awareness that preceded or followed convulsive SE were associated with epileptic discharges on EEG and were classified as non-convulsive seizures. In two patients, add-on cenobamate led to a reduction in tonic-clonic seizures and SE. In all cases, brain MRI showed T2 hyperintensity in pallidi and dentate nuclei. Epilepsy in SSADHD is believed to result from compensatory mechanisms within the GABAergic system. Cenobamate could have a therapeutic effect on patients with SSADHD by modulating GABAA receptors via a non-benzodiazepine site. However, this observation warrants further investigation, including potential benefits beyond seizure control. Epileptologists should consider SSADHD in patients with prolonged non-convulsive seizures or SE, especially when accompanied by developmental, movement, or psychiatric comorbidities and the characteristic neuroradiological features.
2024-10-01 | Characterization of Two rtTA/Ngn2-Transduced Pluripotent Stem Cell Lines from an Individual with SSADH Deficiency
Background/Purpose: Succinic semialdehyde dehydrogenase deficiency (SSADHD) is a rare autosomal recessive disorder caused by mutations in the ALDH5A1 gene. The resulting enzyme defect causes a block in the degradation of γ-aminobutyric acid (GABA) and thus pathologic accumulation of GABA as well as toxic by-products. Clinically this presents in various neurologic disorders such as delayed development. Since current treatment options are limited and symptom related, new therapies are needed. Here we present two inducible rTA/Ngn-2 transduced pluripotent stem cell (iPSC) lines generated from a patient suffering from SSADHD and intended to be used for drug screening in differentiated neurons.
2026-04-28 | Memantine Repurposing for NMDA-mediated Excitotoxicity
Memantine's uncompetitive NMDA receptor antagonism provides neuroprotection against excitotoxicity resulting from GABAergic dysfunction in SSADH deficiency. The drug's voltage-dependent blocking mechanism preserves physiological NMDA signaling while preventing pathological calcium influx during seizure activity and metabolic stress.
2026-04-03 | Postnatal gene restoration in succinic semialdehyde dehydrogenase deficiency (SSADHD) reveals phenotype reversibility.
Succinic semialdehyde dehydrogenase deficiency (SSADHD) is a rare autosomal recessive metabolic disorder due to loss-of-function ALDH5A1 mutations impairing the catabolism of γ-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the brain. In SSADHD, pathologic accumulation of GABA and its metabolic by-product γ-hydroxybutyrate (GHB) corresponds to a clinical syndrome dominated by developmental delay and epilepsy in half of patients with risk of sudden death in adolescence and adulthood. Brain-wide ALDH5A1 gene replacement for SSADHD is unavailable, and whether such treatment will reverse the SSADHD phenotype is unknown. We developed an inducible mouse SSADHD model, Aldh5a1 lox-STOP , enabling Cre-dependent Aldh5a1 restoration to evaluate gene therapy feasibility. In the absence of SSADH, Aldh5a1 lox-STOP mice exhibit hyperactivity and excessive serum GHB levels, culminating in death by ∼postnatal day 22, recapitulating the severe SSADHD condition. Systemic delivery of a blood-brain barrier (BBB)-penetrating adeno-associated virus (AAV) carrying a Cre gene to Aldh5a1 lox-STOP mice leads to brain-wide SSADH restoration, serum GHB level reduction, normalization of hyperactivity, and substantial increase in survival. As a step toward clinical translation, we further assessed an AAV encompassing a functional native promoter (FLnP) of ALDH5A1 tethered to its human coding sequence, namely AAV-FLnP-hALDH5A1. Aldh5a1 lox-STOP mice were effectively rescued when treated with AAV-FLnP-hALDH5A1 packaged in the blood-brain barrier (BBB)-penetrating capsid PHP.eB. These findings provide preclinical proof that SSADH gene replacement therapy is feasible and potentially effective.
2025-08-25 | Rational design and applications of piperazine and cyclohexane ionizable lipids for PKU and SSADH deficiency
A significant challenge of mRNA-based protein replacement therapies is the diminishing efficacy and escalating toxicity associated with repeated dosing of lipid nanoparticles (LNPs). Many existing lipid formulations were originally designed for vaccine and are not optimized for therapeutic applications. We developed two libraries of ionizable lipids—one based on piperazine and the other on a newly introduced cyclohexane structure—with variations in linker and tail groups to enhance molecular diversity. GC Biopharma’s cyclohexane- and piperazine-based LNPs (GCP LNPs) supported stable and high-level expression without inducing liver toxicity under repeated dosing regimens. These LNPs effectively corrected disease markers in mouse models of phenylketonuria (PKU) and succinic semialdehyde dehydrogenase (SSADH) deficiency. Specially, we observed that the rigid structure and chemical stability of cyclohexane-based lipids contributed to sustained delivery performance. These findings offer a promising direction for the development of LNPs suitable for chronic mRNA-based therapies.
2025-08-06 | Severe epilepsy phenotypes in adults with succinic semialdehyde dehydrogenase deficiency: Novel clinical and therapeutic insights from an Italian multicenter retrospective cohort study.
To describe the epileptic phenotypes in a series of adults with succinic semialdehyde dehydrogenase deficiency (SSADHD) and to evaluate the efficacy of novel treatments. We retrospectively reviewed the charts from seven adult patients followed at four Italian Epilepsy Centers. All cases had biallelic variants in the ALDH5A1 gene; three of these were novel: c.1205T>A (p.Val402Glu), c.1630delT (p.Cys544Valfs*15), and c.141C>G (p.Tyr47Ter). Patients (age at last follow-up: 33.8 ± 8.8 years) had moderate motor deficits and variable degrees of intellectual disability, often with psychiatric symptoms. Epilepsy had heterogeneous presentations, with a mean onset age of 13.1 ± 7.7 years. Drug-resistant seizures and convulsive status epilepticus (SE) occurred in five and three patients respectively; two had possible sudden unexpected death in epilepsy. Prolonged episodes of impaired awareness that preceded or followed convulsive SE were associated with epileptic discharges on EEG and were classified as non-convulsive seizures. In two patients, add-on cenobamate led to a reduction in tonic-clonic seizures and SE. In all cases, brain MRI showed T2 hyperintensity in pallidi and dentate nuclei. Epilepsy in SSADHD is believed to result from compensatory mechanisms within the GABAergic system. Cenobamate could have a therapeutic effect on patients with SSADHD by modulating GABAA receptors via a non-benzodiazepine site. However, this observation warrants further investigation, including potential benefits beyond seizure control. Epileptologists should consider SSADHD in patients with prolonged non-convulsive seizures or SE, especially when accompanied by developmental, movement, or psychiatric comorbidities and the characteristic neuroradiological features.
2024-10-01 | Characterization of Two rtTA/Ngn2-Transduced Pluripotent Stem Cell Lines from an Individual with SSADH Deficiency
Background/Purpose: Succinic semialdehyde dehydrogenase deficiency (SSADHD) is a rare autosomal recessive disorder caused by mutations in the ALDH5A1 gene. The resulting enzyme defect causes a block in the degradation of γ-aminobutyric acid (GABA) and thus pathologic accumulation of GABA as well as toxic by-products. Clinically this presents in various neurologic disorders such as delayed development. Since current treatment options are limited and symptom related, new therapies are needed. Here we present two inducible rTA/Ngn-2 transduced pluripotent stem cell (iPSC) lines generated from a patient suffering from SSADHD and intended to be used for drug screening in differentiated neurons.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
2 orphan drug designations for Succinic semialdehyde dehydrogenase deficiency.
2 orphan drug designations for Succinic semialdehyde dehydrogenase deficiency.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
recombinant adeno-associated virus vector-based gene therapy comprising a recombinant AAV genome encoding human ALDH5A1 | gene therapies | FDA | 2026-07-28 | — | Galibra Neuroscience |
3-aminopropyl-butyl phosphinic acid | small molecules | FDA | 2016-12-13 | — | Speragen, Inc. |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.